Logo image of LUNG

PULMONX CORP (LUNG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LUNG - US7458481014 - Common Stock

2.51 USD
+0.05 (+2.03%)
Last: 12/11/2025, 8:00:01 PM
2.51 USD
0 (0%)
After Hours: 12/11/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, LUNG scores 3 out of 10 in our fundamental rating. LUNG was compared to 187 industry peers in the Health Care Equipment & Supplies industry. LUNG has a bad profitability rating. Also its financial health evaluation is rather negative. LUNG shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LUNG has reported negative net income.
In the past year LUNG has reported a negative cash flow from operations.
LUNG had negative earnings in each of the past 5 years.
In the past 5 years LUNG always reported negative operating cash flow.
LUNG Yearly Net Income VS EBIT VS OCF VS FCFLUNG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

LUNG's Return On Assets of -41.04% is on the low side compared to the rest of the industry. LUNG is outperformed by 62.03% of its industry peers.
LUNG's Return On Equity of -94.54% is on the low side compared to the rest of the industry. LUNG is outperformed by 62.03% of its industry peers.
Industry RankSector Rank
ROA -41.04%
ROE -94.54%
ROIC N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
LUNG Yearly ROA, ROE, ROICLUNG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Gross Margin of LUNG (73.30%) is better than 82.89% of its industry peers.
LUNG's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LUNG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
LUNG Yearly Profit, Operating, Gross MarginsLUNG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LUNG has been increased compared to 1 year ago.
LUNG has more shares outstanding than it did 5 years ago.
LUNG has a worse debt/assets ratio than last year.
LUNG Yearly Shares OutstandingLUNG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LUNG Yearly Total Debt VS Total AssetsLUNG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

LUNG has an Altman-Z score of -4.33. This is a bad value and indicates that LUNG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LUNG (-4.33) is worse than 68.98% of its industry peers.
A Debt/Equity ratio of 0.62 indicates that LUNG is somewhat dependend on debt financing.
LUNG has a Debt to Equity ratio of 0.62. This is in the lower half of the industry: LUNG underperforms 61.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -4.33
ROIC/WACCN/A
WACC8.41%
LUNG Yearly LT Debt VS Equity VS FCFLUNG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

LUNG has a Current Ratio of 4.86. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
LUNG has a better Current ratio (4.86) than 77.01% of its industry peers.
LUNG has a Quick Ratio of 4.15. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
LUNG's Quick ratio of 4.15 is fine compared to the rest of the industry. LUNG outperforms 75.94% of its industry peers.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 4.15
LUNG Yearly Current Assets VS Current LiabilitesLUNG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

LUNG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.40%.
The Revenue has grown by 15.59% in the past year. This is quite good.
The Revenue has been growing by 20.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
Revenue 1Y (TTM)15.59%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%5.47%

3.2 Future

The Earnings Per Share is expected to grow by 25.48% on average over the next years. This is a very strong growth
LUNG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.14% yearly.
EPS Next Y-7.1%
EPS Next 2Y1.32%
EPS Next 3Y7.71%
EPS Next 5Y25.48%
Revenue Next Year8.99%
Revenue Next 2Y6.99%
Revenue Next 3Y11.66%
Revenue Next 5Y27.14%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LUNG Yearly Revenue VS EstimatesLUNG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LUNG Yearly EPS VS EstimatesLUNG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LUNG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUNG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUNG Price Earnings VS Forward Price EarningsLUNG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUNG Per share dataLUNG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.32%
EPS Next 3Y7.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LUNG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMONX CORP

NASDAQ:LUNG (12/11/2025, 8:00:01 PM)

After market: 2.51 0 (0%)

2.51

+0.05 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)02-17 2026-02-17/amc
Inst Owners78.21%
Inst Owner Change-12.13%
Ins Owners3.98%
Ins Owner Change37.48%
Market Cap103.54M
Revenue(TTM)91.66M
Net Income(TTM)-56.75M
Analysts80
Price Target5.87 (133.86%)
Short Float %5.15%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.26%
Min EPS beat(2)0.21%
Max EPS beat(2)20.32%
EPS beat(4)4
Avg EPS beat(4)13.38%
Min EPS beat(4)0.21%
Max EPS beat(4)27.7%
EPS beat(8)8
Avg EPS beat(8)16.37%
EPS beat(12)12
Avg EPS beat(12)13.5%
EPS beat(16)15
Avg EPS beat(16)10.22%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.33%
Max Revenue beat(2)1.01%
Revenue beat(4)3
Avg Revenue beat(4)1.37%
Min Revenue beat(4)-0.33%
Max Revenue beat(4)4.53%
Revenue beat(8)6
Avg Revenue beat(8)1.49%
Revenue beat(12)10
Avg Revenue beat(12)3.14%
Revenue beat(16)11
Avg Revenue beat(16)2.17%
PT rev (1m)-14.81%
PT rev (3m)-14.81%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)-1.55%
EPS NY rev (1m)4.85%
EPS NY rev (3m)4.67%
Revenue NQ rev (1m)-7.25%
Revenue NQ rev (3m)-7.25%
Revenue NY rev (1m)-1.08%
Revenue NY rev (3m)-0.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.13
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-1.41
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS2.22
BVpS1.46
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.04%
ROE -94.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.3%
FCFM N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
F-Score2
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.92%
Cap/Sales 0.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.86
Quick Ratio 4.15
Altman-Z -4.33
F-Score2
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)78.82%
Cap/Depr(5y)169.58%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
EPS Next Y-7.1%
EPS Next 2Y1.32%
EPS Next 3Y7.71%
EPS Next 5Y25.48%
Revenue 1Y (TTM)15.59%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%5.47%
Revenue Next Year8.99%
Revenue Next 2Y6.99%
Revenue Next 3Y11.66%
Revenue Next 5Y27.14%
EBIT growth 1Y-0.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.15%
EBIT Next 3Y19.16%
EBIT Next 5Y8.94%
FCF growth 1Y18.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.3%
OCF growth 3YN/A
OCF growth 5YN/A

PULMONX CORP / LUNG FAQ

What is the fundamental rating for LUNG stock?

ChartMill assigns a fundamental rating of 3 / 10 to LUNG.


What is the valuation status for LUNG stock?

ChartMill assigns a valuation rating of 0 / 10 to PULMONX CORP (LUNG). This can be considered as Overvalued.


What is the profitability of LUNG stock?

PULMONX CORP (LUNG) has a profitability rating of 1 / 10.


What is the earnings growth outlook for PULMONX CORP?

The Earnings per Share (EPS) of PULMONX CORP (LUNG) is expected to decline by -7.1% in the next year.